![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » REJECTION OF SLEEP DRUG CAUSES SHARES OF DOV TO NOSE DIVE
REJECTION OF SLEEP DRUG CAUSES SHARES OF DOV TO NOSE DIVE
May 17, 2006
Shares of three pharmaceutical companies declined after indiplon, a sleeping medication, failed to win federal approval Tuesday. Shares of Neurocrine Biosciences Inc., which submitted the application, declined 56 percent to close at $23.86, while Pfizer, Neurocrine's marketing and development partner, saw its stock drop 2 cents to close at $24.87.
North Jersey Media Group
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct